Tango Therapeutics, Inc.
TNGX
$6.61
$0.111.69%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -41.01% | 30.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.01% | 30.97% | |||
| Cost of Revenue | -9.97% | 7.38% | |||
| Gross Profit | 4.59% | -4.12% | |||
| SG&A Expenses | -1.21% | 3.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.88% | 6.43% | |||
| Operating Income | 3.68% | -3.96% | |||
| Income Before Tax | 2.57% | -5.90% | |||
| Income Tax Expenses | 2.94% | -30.61% | |||
| Earnings from Continuing Operations | 2.57% | -5.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.57% | -5.86% | |||
| EBIT | 3.68% | -3.96% | |||
| EBITDA | 3.74% | -4.02% | |||
| EPS Basic | 2.77% | -4.30% | |||
| Normalized Basic EPS | 4.32% | -17.82% | |||
| EPS Diluted | 2.77% | -4.30% | |||
| Normalized Diluted EPS | 4.32% | -17.82% | |||
| Average Basic Shares Outstanding | 0.22% | 1.49% | |||
| Average Diluted Shares Outstanding | 0.22% | 1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||